First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First